单剂量厄他培南预防肝癌选择性肝切除术后手术部位感染：一项倾向评分匹配研究。

Single Dose Based Ertapenem Prophylaxis Reduces Surgical Site Infection after Selective Hepatectomy of Hepatocellular Carcinoma: A Propensity Score Matching Study.

机构信息

Department of Hepatobiliary and Splenic Surgery, Shengjing Hospital, China Medical University, China.

出版信息

Biomed Res Int. 2018 Aug 30;2018:2520191. doi: 10.1155/2018/2520191. eCollection 2018.

DOI:10.1155/2018/2520191

PMID:30246017

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6136539/

Abstract

OBJECTIVE

This study aimed to assess whether a single dose of ertapenem prophylaxis was more effective than other antibiotics to prevent surgical site infection (SSI) after selective hepatectomy for hepatocellular carcinoma (HCC).

METHODS

The data from HCC patients with open hepatectomy between January 2012 and June 2017 in Shengjing Hospital were retrospectively analyzed. These patients were divided into two groups: ertapenem (ER) group, where a single dose of ER was administered; non-ertapenem (NER) group, where NER antibiotics were administered. The SSI rates were compared between two groups before and after matching the propensity scores.

RESULTS

The enrolled patients consisted of 78 in the ER group and 197 in the NER group. After matching the propensity scores, each group was down-selected to 65 patients. The SSI rate among the matched 130 patients was 14.6%, 7.7% occurred in the ER group and 21.5% in the NER group (<0.05). The SSI rates in organ/space of the ER and NER groups were 3.1% and 13.8%, respectively (<0.05).

CONCLUSIONS

A single dose of ER before surgery was more effective in mitigating SSI after selective hepatectomy compared with other antibiotics use. The results imply that the selection of both antibiotics and administration timing is important for the efficacy in preventing SSI.

摘要

目的

本研究旨在评估单剂量厄他培南预防肝细胞癌（HCC）择期肝切除术后手术部位感染（SSI）的效果是否优于其他抗生素。

方法

回顾性分析 2012 年 1 月至 2017 年 6 月在盛京医院行开腹肝切除术的 HCC 患者的数据。这些患者分为两组：厄他培南（ER）组，单次 ER 给药；非厄他培南（NER）组，给予 NER 抗生素。在匹配倾向评分后，比较两组之间的 SSI 发生率。

结果

纳入的患者中 ER 组 78 例，NER 组 197 例。匹配倾向评分后，每组各选择 65 例。在匹配的 130 例患者中，SSI 发生率为 14.6%，ER 组为 7.7%，NER 组为 21.5%（<0.05）。ER 组和 NER 组的器官/间隙 SSI 发生率分别为 3.1%和 13.8%（<0.05）。